All In Biotech

Drug Trial Radar · NCT01235546

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Cesarean Section Optimal Antibiotic Prophylaxis Trial

Last checked: Nov 19, 2026Latest source record: Jul 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,013 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,013

Actual

Start

May 2011

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
Alan TitaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of Texas; University of North Carolina; Mission Hospital; Ochsner Health System; The University of Texas Health Science Center, Houston; Columbia University; University of Utah; University of Mississippi Medical Center
First posted
Nov 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Cesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) study is a large pragmatic multi-center randomized clinical trial designed to evaluate the comparative effectiveness and safety of azithromycin-based extended-spectrum antibiotic prophylaxis (azithromycin plus standard narrow-spectrum cephalosporin) relative to standard single-agent cephalosporin (preferably prior to surgical incision) to prevent post-cesarean infection. Hypothesis: Compared to narrow-spectrum prophylaxis (i.e. cefazolin alone, or clindamycin if cephalosporin allergy) prior to surgical incision, the addition of extended-spectrum prophylaxis (azithromycin + cefazolin) reduces the incidence of post-cesarean infection.

Conditions

  • Endometritis
  • Wound Infection
  • Abscess
  • Surgical Site Infection

Interventions

  • Azithromycin and standard of careDrug

    500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)

  • Placebo and standard of careDrug

    250 cc normal saline, plus standard of care (cephazolin or clindamycin)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)Time frame: Up to 6 weeks after delivery

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Columbia University

    New York, New York

  • Mission Hospital

    Asheville, North Carolina

  • University of North Carolina

    Chapel Hill, North Carolina

  • University of Texas Medical Branch

    Galveston, Texas

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.